An interventional study of TOBACCO CIGARETTES and COMBUSTION-FREE NICOTINE DELIVERY SYSTEMS (C-F NDS) in Gingivitis and Periodontal Diseases, sponsored by Eclat Srl.. Completed at 1 site in Italy. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-08.
Sponsored by Eclat Srl. · Not applicable, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Gingivitis with a site in Italy — 9 open to participants now, 10 under way, 1 of them phase 3. Gingivitis · Italy.
Among the 32 studies in Gingivitis with a site in Italy, this one has the largest enrollment of the 28 interventional ones that give a count, is one of 3 that started in 2021, is one of 22 with no phase, and was the 12th registered.
636 studies on the registry are indexed under Gingivitis; 109 are open to participants now.
Browse Gingivitis studies →9 of the 32 studies in Gingivitis with a site in Italy are open now. Recruiting first, the newest first:
Colgate Palmolive · Sites in Italy
Ages 18–70 · Healthy volunteers
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University · Sites in Italy, China, United Kingdom
Ages 18+ · Healthy volunteers
University of Pavia · Sites in Italy
Ages 18–45 · Women only
University of Pavia · Sites in Italy
Ages 18+ · Women only
Università degli Studi di Ferrara · Sites in Italy
Ages 12–14
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 54 Gingivitis studies recruiting now, 16 (30%) set no upper age limit and 36 (67%) stop at 75 or younger; 11 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 3 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 460 is above the median of 66 across 512 interventional studies indexed under Gingivitis.
Median enrollment 55 across the 28 interventional studies, 95 across the 4 observational. Of the 18 that completed or were terminated, 1 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 32 have an industry lead sponsor. The 10 most frequent:
Eclat Srl. is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Eclat Srl. has 1 study filed under Gingivitis — fewer than ten, so there is no comparison to draw.
1 of the studies in Gingivitis with a site in Italy that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07842991Phase 3Colgate PalmoliveClinical Evaluation of a Toothpaste for Dental Plaque Reduction and Prevention of Gum Problems | 2027-01 |
Add it to your calendar (.ics) → With an account.
Among the 32 studies in Gingivitis with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Although the well-known detrimental effects of conventional cigarette smoking on oral health, there are still lack of evidences about the impact of less harmful alternatives (such as electronic cigarettes or heat not burn products), especially in young smokers with clinical absence of signs of moderate to severe periodontitis.
This study aims to investigate whether cigarette smokers who switch to combustion-free nicotine delivery systems (C-F NDS) undergo measurable improvements in oral health parameters and teeth appearance, comparing short- and long-term impact on periodontal health between smokers continuing with conventional cigarette smoking, those switching to combustion-free nicotine delivery systems (C-F NDS), and never-smokers.
The investigator propose a prospective, multicenter, interventional, open label, randomized, controlled, three parallel-arms study assessing oral health parameters and teeth appearance of 18 months duration.
SMILE is an international, open label, randomized, controlled study of 18 months duration designed to assess whether cigarette smokers switching to combustion free-nicotine delivery systems (C-F NDS) will undergo measurable improvements in oral health parameters and teeth appearance as a consequence of avoiding exposure to cigarette smoke. Five countries have so far agreed to participate: Italy, Moldova, Poland, UK and Indonesia. An amendment will be submitted to the REC once the final two countries are signed up.
A volunteer population of never-smokers and regular smokers of conventional cigarettes with a clinical absence of signs of periodontitis will be recruited. Regular cigarette smokers will be randomized 1:4 ratio either continuing to smoke commercially manufactured conventional cigarettes (Study Arm A) or switching to C-F NDS (Study Arm B). Never Smokers will be assigned to Arm C.The intended minimum number of participants by the end of the study is 460.
Before randomization, all smokers will be reminded of the risks associated with smoking and will be offered a free smoking cessation program according to standard local guidelines and depending on the local availability of antismoking services. Those who decline the invitation will be eligible for recruitment into the study.
Smokers are free to voluntarily quit smoking/C-F NDS and/or withdraw from the study at any time.
Duration:
All participants will attend a total of seven clinics visits: Day -28 to Day -1 - Screening; Day 0 - Enrollment and Randomization (Visit 0); Day 14 (+/-3 days) - Baseline Visit (Visit 1); Day 90 (+/-5 days) - Visit 2; Day 180 (+/-7 days) - Visit 3; Day 360 (+/-10 days) - Visit 4; Day 540 (+/-10 days) - Visit 5.
Each participant will undergo screening within 28 days prior to Visit 0. Eligible participants will be enrolled and randomized on Visit 0. Baseline assessments will be performed at Visit 1, 14 days after Visit 0. The overall duration of study participation for each participant will be a maximum of 568 +/- 10 days.
The randomization sequence will be computer generated, with an allocation ratio of 1:4 (Study Arm A : Study Arm B; Smokers : N-C NDS users) to compensate for an estimated 25% success rate (combined smoking abstinence rate + >90% smoking reduction rate) in the long term. The randomization scheme will be provided to clinical sites via a web-based application set up by the CRO. The staff randomizing the participant will access the web-based application when the participant is with them, entering their participant identification number, date of birth and initials into the program. The allocation will be immediately provided by the program/software.
Product use Regular smokers will continue to smoke their usual brand of conventional cigarette until Baseline on Visit 1. After Visit 1, participants on both Arms A and B will be asked to use only their assigned products ad libitum for the whole duration of the study.
Participants in Arm A will continue smoking their own conventional cigarette brand, as usual.
Participants in Arm B will have the option to try and choose among a selection of either three e-liquids or three tobacco sticks (depending on the C-F NDS they have chosen). They will also be trained and instructed on how to correctly use their chosen C-F NDS. Participants wishing to use a heated tobacco device (HTD) will receive the number of tobacco sticks per day corresponding to the number of cigarettes smoked per day at baseline. Participants wishing to use a vaping product will receive one vaping kit and supply of e-liquids of their choice enough to provide consumption in between supply visits (see Table 2); on average they will receive 4 x 10 ml refill containers per week. Free products will be supplied at each subsequent visit throughout the whole duration of the study.
Participants in Arm C will continue to not smoking or use any form of tobacco or nicotine-containing products.
A prospective monitoring of cigarette consumption, C-F NDS use, and oral hygiene routine will be carried out throughout the study with the tracker APP. Moreover, participants in Arm B will be asked to return all empty, part-used, and unused consumables (tobacco sticks, e-cigarette cartridges, e-liquid refill bottles) at each study visit.
Justification for Study Design
Participants in this study will be a minimum of 18 years of age. This is based on:
To investigate the effects of abstaining from smoking by switching in smokers with clinical absence of periodontitis, a population of both smokers who are intending to make the switch to N-C NDS and never-smokers will be recruited. By the end of the study, it is estimated that a high proportion (approx. 75%) of patients randomized in the Arm B of the study will not be able to achieve success (defined as either complete smoking abstinence or as at least 90% smoking reduction). To account for this, the C-F NDS population will be over sampled and a 1:4 randomization ratio scheme (i.e. for every patient randomized in the continue-to-smoke population, four will be randomized in the C-F NDS population) will be adopted.
It will not be possible to blind participants to the intervention they will be receiving. It will not be possible to blind trial staff when providing the interventions and collecting data. However, data analyses will be conducted blind to Study Arms allocation. All other trial staff who have access to outcome data will remain blinded until prespecified data analyses will be completed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For Arms A and B, subject have to be:
Regular smokers, defined as:
For Arm C, subjects have to be:
Never-smokers, defined as:
Exclusion Criteria:
Moderate to Severe Periodontitis (Stage II, III and IV) based on 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions, which require:
A course of treatment with any medications or substances (other than tobacco/nicotine) which:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participant continues smoking their own cigarette brand.
Other: TOBACCO CIGARETTES
Participant switches to using C-F NDS.
Other: COMBUSTION-FREE NICOTINE DELIVERY SYSTEMS (C-F NDS)
Participant continues to not smoking or using of any nicotine/tobacco products.
Other: NOT SMOKING
Participants in Arm A will continue smoking their own cigarette brand as usual.
Participants in Arm B will trial and familiarize with a selection of C-F NDS in order to choose the product of their preference. They will be trained and counselled on the chosen C-F NDS. Prior to check-out, participants wishing to use a heated tobacco device will receive one kit and a full 2 weeks supply of tobacco sticks of their choice (they will receive a number of tobacco sticks per day corresponding to the number of cigarettes smoked at baseline); those wishing to use a vaping product will receive one vaping kit and a full 2 weeks supply of e-liquids of their choice (they will receive twelve 10 ml refill containers).
Participants in Arm C will continue not smoking or use any form of tobacco or nicotine-containing products.
Modified Gingival Index (MGI)
Percentage (%) mean changes in MGI from baseline at different study time-points
Time frame: Changes in the severity of gingivitis from baseline will be assessed at 3 months, 6 months, 12 months and 18 months
Macpherson Modification of Lobene Tooth Stain Index (MLSI)
Change in MLSI from baseline at different study time-points
Time frame: Changes in extent and severity of tooth stains from baseline will be assessed at 3 months, 6 months, 12 months and 18 months
Dental Discolorations
Percentage (%) mean change in dental shade (L, a\*, b\*) from baseline at different study time-points
Time frame: Changes in dental discolouration from baseline will be assessed at 3 months, 6 months, 12 months and 18 months
Plaque Score Imaging (QLF)
Changes in ΔR30 and ΔR120 from baseline at different study time-points
Time frame: Changes in dental plaque from baseline will be assessed at 3 months, 6 months, 12 months and 18 months
Oral Health Quality of Life (OHQOL)
Changes in OHQOL from baseline at different study time-points
Time frame: Changes in OHQOL score from baseline will be assessed at 3 months, 6 months, 12 months and 18 months
EuroQoL Visual Analog Scale (EQ VAS - QoL)
Changes in EQ VAS-QoL from baseline at different study time-points
Time frame: Changes in the EQ VAS - QoL score from baseline will be assessed at 3 months, 6 months, 12 months and 18 months
Plan to share: No
Ran from Oct 2021 to primary completion in Dec 2024, 38 months.
Of 207 non-industry interventional studies with no phase under Gingivitis, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 17. This study's 38 months is above that.
Counting every sponsor, half of 260 studies reached it within 7 months; a quarter within 3 and three quarters within 15.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Eclat Srl.